Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 336
- Registration Number
- NCT04536337
- Locations
- 🇦🇺
Saint Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇬🇧King's College Hospital, London, United Kingdom
🇨🇳The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Stopping Antiviral Treatment in Chronic Hepatitis B
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 54
- Registration Number
- NCT04431245
- Locations
- 🇭🇰
Man Fung Yuen, Hong Kong, Please Select One ..., Hong Kong
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Enyo Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT04365933
- Locations
- 🇰🇷
ENYO PHARMA Investigative site KR01, Busan, Korea, Republic of
🇨🇳ENYO PHARMA Investigative site TW03, Kaohsiung, Taiwan
🇨🇳ENYO PHARMA Investigative site TW04, Kaohsiung, Taiwan
Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc)
- Conditions
- Occult Hepatitis BLiver Transplant; Complications
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 100
- Registration Number
- NCT04199819
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis
- Conditions
- Hepatitis BCompensated Cirrhosis
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 150
- Registration Number
- NCT04196998
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b
- Conditions
- Chronic Hepatitis b
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 300
- Registration Number
- NCT04195074
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
- Conditions
- Hepatocellular CarcinomaCompensated CirrhosisHepatitis B, Chronic
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Qing XIe
- Target Recruit Count
- 4000
- Registration Number
- NCT04160897
- Locations
- 🇨🇳
Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection
- Conditions
- HBV CoinfectionHCC
- Interventions
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT04032860
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
- Conditions
- Hepatitis BViral Hepatitis
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT03933384
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
- Conditions
- Hepatitis BAcute-On-Chronic Liver Failure
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 150
- Registration Number
- NCT03920618
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.